PMID: 8939641Dec 1, 1996Paper

Gram-positive commensal bacteria for mucosal vaccine delivery

Current Opinion in Biotechnology
V A FischettiG Pozzi

Abstract

To avoid the use of engineered pathogens for vaccine delivery, systems have been developed that allow the expression of heterologous antigens in commensal Gram-positive bacteria. In some cases, both a serum IgG and secretory IgA response are induced to the recombinant protein after vaccination, verifying the validity of the approach. These live recombinant bacteria may be used in the future to introduce a protective immune response to pathogenic microorganisms after mucosal colonization.

References

Nov 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·J L MichelF M Ausubel
Sep 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P W O'TooleG Lindahl
May 1, 1992·Virology·J TartagliaM Riviere
Jul 24, 1992·Cell·O SchneewindV A Fischetti
Jun 6, 1991·Nature·C K StoverG F Hatfull
Jan 31, 1991·Biochemical and Biophysical Research Communications·S InoueH Suginaka
Mar 1, 1991·Molecular Immunology·J H EldridgeR M Gilley
Mar 1, 1985·The Journal of Experimental Medicine·K F JonesV A Fischetti
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D G Heath, P P Cleary
Jan 1, 1986·Archives of Oral Biology·M Svanberg, G Westergren
Oct 15, 1987·European Journal of Biochemistry·A OlssonM Uhlén
Jan 1, 1984·Biotechnology & Genetic Engineering Reviews·G L SmithB Moss
Jan 16, 1984·European Journal of Biochemistry·B GussJ Sjödahl
Aug 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·G N PhillipsV A Fischetti
Jul 18, 1995·Proceedings of the National Academy of Sciences of the United States of America·D MedagliniV A Fischetti
Mar 2, 1962·Science·R M COLE, J J HAHN
Apr 26, 2011·Biosensors & Bioelectronics·Lídia CarvalhoMaria H Fernandes

❮ Previous
Next ❯

Citations

Sep 15, 2000·Journal of Immunological Methods·P S DaughertyG Georgiou
May 1, 1997·Trends in Biotechnology·S Ståhl, M Uhlén
Jun 1, 2002·Journal of Biotechnology·Patrik SamuelsonStefan Ståhl
Oct 11, 2003·Biotechnology Advances·I Benhar
Jul 1, 1997·Nature Biotechnology·J D Clements
Jul 31, 1998·Immunology and Cell Biology·J Kovarik, C A Siegrist
Jul 14, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Carina ValenteRaquel Sá-Leão
Jul 27, 2002·Journal of Biotechnology·Henrik WernérusStefan Ståhl
Aug 7, 2013·Critical Reviews in Microbiology·Peng-Song Li, Hu-Chun Tao
Jan 11, 2003·Biotechnology & Genetic Engineering Reviews·Walter MaglianiLuciano Polonelli
Aug 29, 2014·The Journal of Microbiology·Jae-Hyung JoHyune-Hwan Lee
Jan 30, 2020·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·B Gunasekaran, K M Gothandam
Jun 22, 2002·FEMS Microbiology Letters·Henrik Wernérus, Stefan Ståhl
Jan 3, 2021·Biotechnology Advances·Ezio RiccaRachele Isticato
Mar 6, 1999·Microbiology and Molecular Biology Reviews : MMBR·W W Navarre, O Schneewind
Jun 25, 2015·Microbiology Spectrum·Rachele Isticato, Ezio Ricca
Jul 1, 1997·Applied and Environmental Microbiology·S LiljeqvistS Ståhl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.